Background An autoimmune cause of adrenocorticotropin (ACTH)-deficiency is presented, as it is known to be a characteristic feature of lymphocytic hypophysitis, a disease of the pituitary gland considered to be autoimmune.
Introduction
Adrenocorticotropin (ACTH)-deficiency may be caused by genetic abnormalities or may be secondary to destructive pituitary lesions such as trauma, tumours, surgery, irradiation and infiltrative diseases. However, the origin of ACTHdeficiency is uncertain in most cases. An autoimmune cause of ACTH-deficiency has been proposed, as it is known to be a characteristic feature of lymphocytic hypophysitis, a disease of the pituitary gland considered to be autoimmune [1, 2] . Furthermore, as in many autoimmune disorders, there is a female preponderance and isolated ACTHdeficiency is also known to coexist with several other autoimmune endocrine disorders [3 -6] .
Detection of autoantibodies is a valuable tool in the diagnostic workup of autoimmune diseases. Several reports have described pituitary autoantibodies in patients with lymphocytic hypophysitis and isolated ACTH-deficiency. Conventional immunofluorescence methods detected pituitary autoantibodies in ACTH-deficient patients that reacted with rat pituitary gland and AtT20 murine cells [7] [8] [9] .
A drawback of immunofluorescence in regards to corticotrophs relates to the detection of nonspecific binding of autoantibodies by Fc receptors [10, 11] . An immunoblotting technique has allowed more detailed characterization of targeted pituitary autoantigens by molecular weight [12, 13] . Recently, a 22-kDa and a 49-kDa pituitary autoantigen have been identified as growth hormone and neurone-specific enolase, respectively [14 -16] . Using a radioligand assay, Tanaka and colleagues identified autoantibodies against human growth hormone, pituitary gland specific factor 1a (PGSF 1a) and PGSF2, in patients with lymphocytic hypophysitis, isolated ACTH deficiency or idiopathic thyroid-stimulating hormone (TSH) deficiency [17] .
In previous reports, only limited numbers of patients with isolated ACTH-deficiency have been tested for pituitary autoantibodies. The aim of our study was to examine pituitary autoantibodies in a large number of patients with ACTHdeficiency of possible autoimmune aetiology. We have used an immunoblotting assay with human pituitary cytosol as antigen in the detection of pituitary autoantibodies, which enables identification of target autoantigens by molecular weight and avoids the potential problems of species specificity. We also aimed to correlate the occurrence of pituitary autoantibodies to the clinical and immunological features of the patients.
Subjects
Sixty-five patients, 63 women and two men diagnosed with ACTH-deficiency of unknown origin at the Department of Endocrinology, Centre for Postgraduate Medical Education (Warsaw, Poland), participated in the study. At sampling, the mean age of the patients was 49 years (range 18 -76) and the median duration of disease from diagnosis was 1 year (range 0 -16). However, in many cases a long-term period of subclinical complaints, comprising weakness and fatigability, mainly following stressful conditions, preceded diagnostic procedures.
Sera from 57 healthy Swedish subjects, 52 women and five men, mean age 44·4 years (range 19 -65), with no documented allergic or endocrine disease or medication were used as controls in the pituitary autoantibody analysis. The study was approved by the Ethics Committees of the Centre for Postgraduate Medical Education (Warsaw, Poland) and the Karolinska Hospital (Stockholm, Sweden). All subjects participated after giving informed consent.
Methods

Clinical and immunological investigations in patients with ACTH-deficiency
The diagnosis of ACTH-deficiency in patients was based on clinical characteristics and hormonal investigation including simultaneous plasma ACTH (by immunoradiometric method) and cortisol (by radioimmunoassay) determinations as well as 17-hydroxycorticosteroids (17-OHCS) urinary excretion (by the Silber and Porter method) in basal conditions and during 2 days of synthetic ACTH administration, as described previously [6, 18] Pituitary function was further evaluated in all patients by measurements of serum levels of prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and (TSH), while the thyroid function was evaluated by free thyroxin determinations. In women, serum estradiol levels were measured, and in men testosterone levels. Patients were asked about coexisting endocrine and autoimmune disorders as well as any previous pregnancies. Data relating to all previous pituitary imaging examinations were collected.
In all patients' sera, autoantibodies against thyroglobulin (aTg) and thyroid microsomes (aMIC) were examined (Thymune T and Thymune M, respectively, Murex Diagnostics, Dartford, UK) (normal values: up to 1 /120). Autoantibodies against thyroid peroxidase (aTPO) were determined as described previously [19] (pathological values: equal or greater than 1 / 800).
Analysis of autoantibodies to pituitary cytosolic proteins
The analysis of pituitary autoantibodies was performed as previously described [12, 13] . Normal human autopsy pituitary tissue was homogenized in phosphate-buffered saline (PBS) (pH 7·4) with protease inhibitors (leupeptin, pepstatin, phenylmethylsulphonylfluoride, ethylendiamine tetraacetate and ethyleneglycol tetraacetate) and centrifuged at 400 × g and then 100 000 × g to give a cytosolic fraction. The cytosol was depleted of immunoglobulin G using protein A-Sepharose (Pharmacia Biotech AB, Uppsala, Sweden) and fractionated (50 µ g well − 1 ) on sodium dodecylsulphate (SDS)-polyacrylamide gels (10% running gel, 4% stacking gel) by electrophoresis under reducing conditions. Pre-stained molecular weight standards were used in every experiment (Biorad, Hercules, CA, USA). Separated proteins were transferred by wet blotting to polyvinylidene difluoride membranes (NEN Life Science Products, Boston, MA, USA). After blocking with 5% nonfat milk in PBS (pH 7·4) for 1 h, lanes were incubated with patient or control subject serum diluted at 1 : 50 in PBS (pH 7·4) containing 1% nonfat milk on a shaker overnight at 4 ° C. Membranes were washed first in PBS containing 0·05% Tween 20 and then PBS, followed by incubation with alkaline phosphataseconjugated sheep antihuman IgG antiserum (Sigma-Aldrich Inc, Saint Louis, MO, USA) diluted at 1 : 4000 in PBS containing 1% nonfat milk for 1·5 h at room temperature on a shaker. After repeated washing, membranes were incubated with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (NEN Life science Products, Boston, MA, USA) until colour development was optimal. Serum from a patient previously shown to have strong immunoreactivity against a 49-kDa pituitary autoantigen was used as a positive control in each experiment. All sera were analyzed twice and results reported by one observer blinded to the status of the serum samples. Immunoreactivity was reported as negative , positive or strongly positive. Negative result: no band of immunoreactivity observed. Positive result: a distinct, sharp band of immunoreactivity detected above background staining. Strongly positive result: a distinct, sharp band of immunoreactivity detected above background staining but of greater width and colourintensity, indicating a relatively high autoantibody titre.
Statistical analysis
Statistical analyses were performed using Statistica, StatSoft Inc (version 6·1), Tulsa, OK, USA. χ 2 -test with Yates' correction was used when comparing immunoreactivities to pituitary autoantigens in patients vs. control subjects. The two-tailed Fisher exact test was used when comparing clinical and immunological parameters in patients with positive pituitary immunoreactivity vs. patients with negative pituitary immunoreactivity. Statistical significance was set at P < 0·05. Clinical parameters included gender (male /female), age at diagnosis, duration of disease, pregnancy in the past (presence / absence), other pituitary insufficiency (presence / absence) and other endocrine disorders. Immunological parameters included a clinical history of other autoimmune diseases and circulating aTPO, aTG or aMIC autoantibodies (presence / absence).
Results
Clinical and immunological findings in patients with ACTH-deficiency
Pituitary function tests in patients revealed prolactin deficiency in a 21-year-old female, low TSH in a 40-year-old woman and low gonadotropin levels in two elderly women. Thus in 61 / 65 patients, isolated secondary adrenal insufficiency was diagnosed.
Coexisting autoimmune diseases ( n = 45) were found in 33 / 65 (51%) patients (Table 1 ). Ten of the 33 patients suffered from multiple coexisting autoimmune diseases. Thyroid autoimmune diseases were most common. Positive results for the thyroid autoantibody analysis were found in 55 / 65 (85%) patients (Table 1 ). In 31 patients thyroid autoantibodies were present without laboratory signs of hypothyroidism.
A history of previous pregnancy was noted in 53 / 63 (84%) of the female patients.
Magnetic resonance imaging of the pituitary performed in 18 patients revealed a partially empty sella in six cases, an empty sella in one patient and a slightly enlarged pituitary in three patients. In the remaining eight patients no abnormalities were visualized.
Analysis of autoantibodies to pituitary cytosolic proteins
Duplicate immunoblotting runs revealed positive immunoreactivity against a 36-kDa pituitary cytosolic protein in 12 of 65 (18·5%) patients and two of 57 (3·5%) control subjects. The difference between patients and control subjects was statistically significant P = 0·0214 ( χ 2 -test with Yates' correction). When taking only those subjects with strong immunoreactivity on both runs into account (six patients vs. two control subjects) the significance was lost, P = 0·3642. Table 2 (patient nos 11 -22) shows the clinical data of the 12 patients with positive 36-kDa immunoreactivity. Statistical analysis revealed no differences in the clinical parameters between patients testing positive or negative for this immunoreactivity; except, the group of patients with positive 36-kDa immunoreactivity had a higher frequency of aTG autoantibodies ( P = 0·014) (Fisher's exact test, two-tailed, not shown in the tables).
Positive immunoreactivity to a 49-kDa pituitary cytosolic protein was observed in sera from 14 of 65 (21·5%) patients with isolated ACTH deficiency and in five of 57 (8·8%) control subjects. Statistical calculation demonstrated that patients with ACTH deficiency had a tendency toward a higher frequency of immunoreactivity against this autoantigen compared with control subjects, P = 0·0910 ( χ 2 -test with Yates' correction). When only subjects with strong immunoreactivity in both runs were analyzed (eight patients vs. three blood donors) the tendency was lost, P = 0·2990. Clinical data from the 14 patients with autoantibodies against the 49-kDa pituitary protein are shown in Table 2 (patient nos [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Comparison of clinical and immunological parameters of these 14 patients to the 51 patients with no immunoreactivity against this protein showed no statistical differences.
Four patients reacted against both the 36-kDa and 49-kDa pituitary autoantigens in duplicate immunoblotting runs (patient nos 11-14, Table 2 ), while 43 patients exhibited no immunoreactivity against these pituitary autoantigens. A number of other pituitary cytosolic proteins were also detected by individual sera, but there were no significant patterns nor differences between the patients and the control subjects. Figure 1 shows immunoreactivity against the 36-kDa and 49-kDa pituitary autoantigens in some patients' sera.
MRI of the pituitary region was performed in 18 / 65 (28%) of patients. Statistical analysis of this subgroup of patients revealed no differences in imaging findings between the patients with or without 36-kDa and 49-kDa immunoreactivity, respectively.
Discussion
The anterior pituitary gland consists of five different cell types with six individual hormone synthesis pathways. Therefore, it is likely that patients with a range of pituitary hormone deficiencies due to lymphocytic hypophysitis exhibit various spectrums of pituitary autoantibodies. To date, only four autoantigens have been identified in a very limited number of patients with isolated ACTH deficiency: enolase ( α and γ isoforms) [13, 16, 20, 21] , human growth hormone, PGSF1a and PGSF 2 [17] . Sauter et al . detected positive immunostaining, which was concentrated in secretory granules in rat pituitary corticotrophs in a man with isolated ACTH-deficiency [9] , but this protein is still uncharacterized.
In the current study, we have examined pituitary autoantibodies in a large group of patients with possible autoimmune ACTH-deficiency. We have identified a 36-kDa pituitary protein as a minor target of autoantibodies in ACTHdeficiency, with a small fraction (12/65, 18·5%) of the ACTHdeficient patients studied being positive. To our knowledge, this is the first report of immunoreactivity against a pituitary protein of this molecular weight. Until more careful characterization of this protein is performed, we can only speculate on the nature of this autoantigen. As many known endocrine autoantigens are intracellular enzymes involved in hormone synthesis [22] , it is tempting to suggest that this is also the case with the 36-kDa pituitary autoantigen. The finding of 36-kDa immunoreactivity in sera from a couple of control subjects may indicate that the specificity of this autoantibody is not 100%. To clarify the relevance for this autoantibody as a marker for autoimmune ACTH-deficiency, further studies are needed. Complete identification of the 36-kDa pituitary autoantigen is necessary, and the cut-off level for autoantibody titres in healthy subjects needs to be defined. The occurrence of 36-kDa immunoreactivity in patients with different pituitary diseases also needs to be investigated.
We have also shown that some patients with ACTHdeficiency have autoantibodies against a 49-kDa pituitary cytosolic protein; however, not significantly more frequent than control subjects. Immunoreactivity against this autoantigen has been shown previously in 70% of biopsy-proven lymphocytic hypophysitis patients and in 55% of patients with suspected lymphocytic hypophysitis, including cases of isolated ACTH-deficiency [13] , as well as in idiopathic hypopituitarism [23] . The 49-kDa pituitary autoantigen has been identified as neurone-specific enolase, but contradictory data on the importance of enolase autoantibodies as markers for neuroendocrine autoimmunity have been published [16, 20, 21] .
Sixty-six percent (43/65) of the patients with ACTHdeficiency in our study did not show any immunoreactivity against the 36-kDa or 49-kDa pituitary autoantigens. There may be several reasons for this observation. First, the ACTH-deficiency in these patients may not be caused by autoimmune destruction of corticotrophs but other causes such as genetic abnormalities. Second, it is possible that some pituitary autoantibodies in ACTH-deficient patients cannot recognize the denatured form of antigen used in our immunoblotting assay. This phenomenon has been recognized for antiglutamic acid decarboxylase (GAD) autoantibodies in type 1 diabetes mellitus patients who rarely recognize denatured GAD. Instead, GAD autoantibodies are detectable by immunoprecipitation under nondenaturing conditions [24] . We chose to use human pituitary cytosol as the substrate in our study, as most endocrine autoantigens are known to be cytosolic. However, it is possible that additional target autoantigens are bound to pituitary cell membranes [12, 25] .
Many authors have suggested a relationship between the development of pituitary autoimmune disease and pregnancy [16, 26, 27] . As the features of secondary adrenal insufficiency are not as dramatic as in Addison's disease, it is probable that subclinical ACTH deficiency could follow autoimmune hypophysitis developed during pregnancy. The present series of patients with ACTH-deficiency includes a striking dominance of women: 63 females vs. two males. Fifty-one of 63 women had been pregnant 5 -40 years before the study but only two women had pregnancies within the last 2 years. These two women both showed positive immunoreactivity to the 36-kDa pituitary autoantigen. Thus, a probable cause of the patients' lack of immunoreactivity against pituitary autoantigens could be the long duration of disease, resulting in complete destruction of corticotrophs (i.e. antigen material) and subsequent reduction in autoantibody titres. Selective loss of corticotroph cells in patients with lymphocytic hypophysitis has been reported [28 -30] .
A striking feature of this cohort of ACTH-deficient patients is the high frequency of associated autoimmune disease, in particular hypothyroidism. Co-existent autoimmune disease is also a feature of patients with biopsy-proven lymphocytic hypophysitis [31, 32] . Patients with autoantibodies to the 36-kDa pituitary autoantigen did show a higher frequency of aTG autoantibodies than patients without immunoreactivity against this pituitary autoantigen, but we could not correlate immunoreactivity to the 36-kDa or 49-kDa pituitary autoantigen to symptomatic hypothyroidism or any other specific autoimmune disease.
In conclusion, a 36-kDa pituitary protein has been shown in this study to be a novel target of autoantibodies in ACTHdeficiency. The precise role of autoantibodies in the pituitary disease process, and their possible clinical utility, is still to be determined.
